Overview

Open-label Study to Investigate Systemic Exposure in Adult and Pediatric Atopic Dermatitis Patients Treated 8.5 Days With Pimecrolimus Cream 1% Under Occlusion

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study will access the degree to which pimecrolimus is absorbed from pimecrolimus cream 1% into the blood when applied repeatedly under occlusion (i.e. areas treated wrapped in a plastic film) over 8 days in patients with moderate to severe atopic eczema.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis

Treatments:

Pimecrolimus
Tacrolimus